WO2023208982 - CRYSTAL FORM OF A PDE4 INHIBITOR
National phase entry:
Publication Number
WO/2023/208982
Publication Date
02.11.2023
International Application No.
PCT/EP2023/060886
International Filing Date
26.04.2023
Title **
[English]
CRYSTAL FORM OF A PDE4 INHIBITOR
[French]
FORME CRISTALLINE D'UN INHIBITEUR DE PDE4
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
AMADEI, Francesco
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
BASSANETTI, Irene
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
FORNASARI, Luca
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
Priority Data
22170229.3
27.04.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1214 | |
| EPO | Filing, Examination | 5952 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3310 |
Total: 11645 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to the crystal Form 2 of the compound of formula (I), to the process for its isolation and to the pharmaceutical compositions thereof. The present invention also relates to the crystal Form 2 of the compound of formula (I) for use as a medicament and for the manufacture of a medicament for the prevention and/or treatment of an inflammatory respiratory or obstructive respiratory disease.[French]
La présente invention concerne la forme cristalline 2 du composé de formule (I), son procédé d'isolation et ses compositions pharmaceutiques. La présente invention concerne également la forme cristalline 2 du composé de formule (I) pour une utilisation en tant que médicament et pour la fabrication d'un médicament pour la prévention et/ou le traitement d'une maladie respiratoire inflammatoire ou obstructive respiratoire.